Business Wire

REPLY

15.5.2024 14:01:32 CEST | Business Wire | Press release

Share
Reply Spearheads the M365 Copilot Adoption and Introduces Immersive M365 Copilot Experience at Milan Xchange 2024

Reply, with its company WM Reply, has collaborated with Microsoft to fully harness and promote the capabilities of Microsoft 365 Copilot and will showcase its transformative potential at the Milan 2024 Xchange event on May 15-16 through a live immersive experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515336953/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Reply, with its company WM Reply, has collaborated with Microsoft to fully harness and promote the capabilities of Microsoft 365 Copilot. As a partner in Microsoft’s Early Access Program (EAP), Reply has leveraged its extensive experience and insights to assist organisations in achieving early successes with Copilot. This collaboration aims to tailor Copilot solutions to specific business needs, from automating routine tasks and enhancing data security to accelerating app development and improving collaboration. (Graphic: Business Wire)

As a partner in Microsoft’s Early Access Program (EAP), Reply has leveraged its extensive experience and insights to assist organisations in achieving early successes with Copilot. This collaboration aims to tailor Copilot solutions to specific business needs, from automating routine tasks and enhancing data security to accelerating app development and improving collaboration. A tailored roadmap, developed in collaboration with Microsoft, guides organisations through the implementation and maximisation of Copilot’s capabilities.

Understanding the importance of adoption, Reply has developed a five-step approach to ensure that the benefits of Copilot M365 are accessible to a wide corporate audience. This approach aligns with Microsoft AI Lab’s vision and focuses on integrating Copilot into daily operations effectively. The below Copilot maturity model framework aims to help customers assess their current state and their desired state with Copilot, and to identify the gaps and the actions needed to achieve their goals:

  1. Approach – Exploring the art of the possible, technical readiness and align with company strategy.
  2. Assess – Plan a pilot where we take the early-adopters on a journey with measurement qualitative and quantitative. Use those results to create a business case and roll-out plan.
  3. Adopt – Set-up a CoE for Copilot. Land key messages and provide training using a scenario/functional specific approach.
  4. Embed – Make Copilot Business as Usual at or your organisation. Manage a dynamic licensing approach and stay on top of new features.
  5. Extend – Bring the power of copilot to wider application.

Immersive Introduction at Milan Xchange

Held annually, Reply’s Xchange brings together technology leaders and innovators to explore the latest in digital solutions and strategies. This year, Reply will debut the “AI-Scape Room," an immersive virtual escape room experience developed by WM Reply and powered by Microsoft Copilot for Microsoft 365. This demonstration will highlight how Copilot enhances productivity, security, and collaboration within business processes through advanced AI integration.

The AI-Scape Room is designed to foster teamwork and communication as participants collaborate to solve puzzles and challenges with the assistance of Copilot’s AI-driven insights. The bespoke escape room is an opportunity for all participants to experience, explore and discover how to utilise M365 copilot as the hands-on challenges provide valuable insights into the potential of AI in enhancing workplace efficiency and engagement.

For more information on Reply’s M365 Copilot Adoption approach, the AI-Scape Room and Reply's AI-based solutions, visit: www.reply.com

Reply

Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

WM REPLY

WM Reply is the Reply Group company specialising in improving employees day-to-day lives through modern workplace solutions and connecting consumers to products and experiences they love online. We support our clients from beginning to end; designing and building their solution and easing adoption. Making sure our clients are not just enjoying the benefits of the cloud but exploiting them as well. We are recognised as leaders within Sitecore, Dynamics 365, Office 365 and the products within such as SharePoint, Power Platform, Yammer and Microsoft Teams. A Microsoft Gold Partner five times over! We have a colourful team who are famous for their imagination, delivery, passion for technology and most importantly, their pride in delivery. www.wm.reply.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515336953/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye